Journals / Çocuk Dergisi / 2020 / Cilt: 20 - Sayı: 3

Pathogenesis and Biology of Graft-Versus-Host Disease

GvHH Patogenezi ve Biyolojisi

Pages
115–119
Publication Date
2020-12-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review presents current literature studies on factors that affect GvHD biology, including classical and nonclassical human leukocyte antigen (HLA) genes, minor HLA antigens, cytokines, chemokines, and costimulatory molecules.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Graft-versus-host disease (GvHD) is an important complication that usually develops after hematopoietic stem cell transplantation and affects the success of the transplant.
📊
Key Findings & Data:It is important to identify the pathogenesis, risk factors, prognosis, and biomarkers for the management and prevention of GvHD, as welll as the development of treatment strategies for GvHD.
💡
Conclusion & Impact:This review presents current literature studies on factors that affect GvHD biology, including classical and nonclassical human leukocyte antigen (HLA) genes, minor HLA antigens, cytokines, chemokines, and costimulatory molecules.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Graft versus host hastalığı · hematopoetik kök hücre nakli · insan lökosit antijenleri

Abstract

Graft-versus-host disease (GvHD) is an important complication that usually develops after hematopoietic stem cell transplantation and affects the success of the transplant. It is important to identify the pathogenesis, risk factors, prognosis, and biomarkers for the management and prevention of GvHD, as welll as the development of treatment strategies for GvHD. This review presents current literature studies on factors that affect GvHD biology, including classical and nonclassical human leukocyte antigen (HLA) genes, minor HLA antigens, cytokines, chemokines, and costimulatory molecules.

Özet

Graft versus host hastalığı (GvHH) genellikle hematopoetik kök hücre nakli (HKHN) sonrası gelişen ve nakil işleminin başarısını etkileyen önemli bir komplikasyondur. GvHH’nin iyi yönetilmesi, önlenmesi ve tedavi stratejilerinin geliştirilebilmesi için patogenezi, risk faktörleri, prognozu ve biyobelirteçlerinin tespit edilmesi önemlidir. Bu derlemede GvHH biyolojisinde etkili olan faktörlerden klasik ve klasik olmayan insan lökosit antijenleri (HLA) genleri, minör HLA antijenleri, sitokinler, kemokinler ve kostimülatör moleküller ile ilgili literatürde yer alan güncel çalışmalar sunulmuştur.

🔖

Cite This Article

KIVANÇ, D., OĞUZ, F. S. (2020). Pathogenesis and Biology of Graft-Versus-Host Disease. Çocuk Dergisi, Cilt: 20 - Sayı: 3, 115–119. https://ajindex.com/articles/246783

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferrara JL, Reddy P. Pathophysiology of graft versus-host disease. Semin Hematol 2006;43(1):3-10
  2. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020 Feb;7(2):e157-e167
  3. Carpenter PA, MacMillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am 2010 Feb;57(1):273-95
  4. Patel KK, Patel AK, Ranjan RR, Shah AP. Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an ımmunocompetent patient. Indian J Hematol Blood Transfus 2010 Sep;26(3):92-5
  5. Saffo S, Peng C, Kibbi N, Patel N, Robert ME, Adekolu E, et al. Graftversus- host disease after pancreatic transplantation. ACG Case Rep J 2019 Sep 12;6(9):e00214
  6. Batra A, Cottler-Fox M, Harville T, Rhodes-Clark BS, Makhoul I, Nakagawa M. Autologous graft versus host disease: An emerging complication in patients with multiple myeloma Bone Marrow Res 2014;2014:891427
  7. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012 Jan 5;119(1):296-307
  8. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966-67;62:21-78
  9. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003 Jul 15;102(2):756-62
  10. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005 Dec;11(12):945-56
  11. Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Preface to the series. Biol Blood MarrowTranspl 2015 Mar;21(3):387-8
  12. Apostolova P, Zeiser R. The role of danger signals and ectonucleotidases in acute graft-versus- host disease. Hum Immunol 2016 Nov;77(11):1037-47
  13. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-ver